Citigroup
BLSM

Citigroup’s BlossomHill Therapeutics BLSM Stock Holding History

Citigroup’s Portfolio BLSM Stock Details BLSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23.8K Buy
+1,279
New +$25.4K ﹤0.01% 4935

Other funds holding BLSM

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Monashee Investment Management
Monashee Investment Management Boston, Massachusetts $33.4M AUM 92.4% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Aster Capital Management
Aster Capital Management Dubai, United Arab Emirates $275M AUM 18.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Citigroup's BLSM Position: Q3 2026 in Review

Citigroup opened a new position in BlossomHill Therapeutics (BLSM) in Q3 2026: 1,279 shares worth $23.8K. The stake represents ﹤0.01% of the portfolio and ranks #4935 among its holdings.

11 funds tracked by Wall St. Rank hold BLSM as of Q3 2026.

  • Citigroup held 1,279 shares of BlossomHill Therapeutics worth $23.8K as of Q3 2026.
  • BlossomHill Therapeutics was a new Citigroup position in Q3 2026.
  • BlossomHill Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4935 holding.
  • 11 funds tracked by Wall St. Rank held BlossomHill Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.